The first comprehensive analysis of clinical trials in the UK has found the country remains a global leader in medical ...

Chinese biotech RemeGen (SHA: 688331) has reported positive late-stage clinical trial data for its dual-target fusion protein ...

US health technology assessor the Institute for Clinical and Economic Review (CER), in collaboration with researchers from ...

The All-Russian Union of Patients (VSP) has called on Russia’s Deputy Prime Minister, Tatyana Golikova, to expand the list of ...

South Korea’s Samsung Bioepis presented data, including the budget impact analysis on ustekinumab biosimilars’ cost savings ...

The Russian pharmaceutical market grew by 10% in value terms to 2.85 trillion roubles ($85 billion) in 2024, which was mainly ...

Cambridge, USA-based Merida Bioscienes, a biotechnology company pioneering a new class of precision therapeutics designed to ...

The European Commission (EC) has granted marketing authorization to Rinvoq (upadacitinib; 15mg, once daily), from US pharma ...

US biotech Annovis Bio has reported encouraging findings for its experimental therapy buntanetap in a subgroup of patients ...

Swiss biopharma Idorsia (SIX: IDIA) has received approval from the US Food and Drug Administration for an updated label on ...

Licensing agreements for Chinese drug candidates hit a record high in 2024, with large pharma in-licensing 28% of innovator drugs from Chinese biopharma companies.

For more than four decades since the passage of the Hatch-Waxman Act, the US generic drug market has provided patients with ...